OKYOOKYO Pharma Ltd

Nasdaq okyopharma.com


$ 1.44 $ -0.02 (-1.32 %)    

Wednesday, 15-May-2024 15:32:27 EDT
QQQ $ 452.83 $ 3.91 (0.87 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 3.17 (0.6 %)
TLT $ 92.14 $ 1.28 (1.41 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 1.49
$ 1.44
$ 1.43 x 100
$ 1.50 x 244
$ 1.44 - $ 1.44
$ 0.92 - $ 3.07
10,912
na
931,250
$ 1.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

 why-salarius-pharmaceuticals-shares-are-trading-higher-by-around-31-here-are-20-stocks-moving-premarket

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter re...

 relief-for-dry-eye-disease-okyo-pharmas-candidate-shows-durable-pain-relief-in-mid-stage-study

Latest findings from OKYO Pharma's Phase 2 trial on OK-101 for dry eye disease. Significant reductions in ocular pain, impr...

 hc-wainwright--co-maintains-buy-on-okyo-pharma-raises-price-target-to-7

HC Wainwright & Co. analyst Yi Chen maintains OKYO Pharma (NASDAQ:OKYO) with a Buy and raises the price target from $6 t...

 hc-wainwright--co-maintains-buy-on-okyo-pharma-raises-price-target-to-5

HC Wainwright & Co. analyst Yi Chen maintains OKYO Pharma (NASDAQ:OKYO) with a Buy and raises the price target from $4 t...

 hc-wainwright--co-reiterates-buy-on-okyo-pharma-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates OKYO Pharma (NASDAQ:OKYO) with a Buy and maintains $4 price target.

 okyo-pharma-announces-last-patient-enrolled-in-ok-101-phase-2-trial-to-treat-dry-eye-disease-has-completed-final-protocol-visit

In addition, data analysis plans for the trial have now been finalized and submitted to FDA for feedback, in anticipation of da...

 hc-wainwright--co-initiates-coverage-on-okyo-pharma-with-buy-rating-announces-price-target-of-4

HC Wainwright & Co. analyst Yi Chen initiates coverage on OKYO Pharma (NASDAQ:OKYO) with a Buy rating and announces Pric...

 okyo-pharma-reports-filing-of-an-investigational-new-drug-ind-application-for-ok-101-to-treat-neuropathic-corneal-pain

Study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION